{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:11:06Z","timestamp":1784927466411,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Myasthenia gravis (MG) is a common autoimmune disease with acquired neuromuscular transmission disorders. Recently, monoclonal antibodies have been shown to successfully treat a variety of diseases.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> In this meta-analysis, an appropriate search strategy was used to search eligible randomized controlled trials (RCTs) on different monoclonal antibodies to treat patients with MG published up to September 2021 from the embase, PubMed, and Cochrane Library. We assessed the average difference or odds ratio between each drug and placebo and summarized them as the average and 95% confidence interval (CI), respectively.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In indicators of efficacy, patients receiving eculizumab (MD, \u22121.9; 95% CI, \u22123.2\u20130.76) had decreases in MG-ADL scores compared to placebo. In addition, only eculizumab (MD, \u22123.1; 95% CI, \u22124.7\u20131.5) and efgartigimod (MD, \u22121.4; 95% CI, \u22122.1\u20130.68) showed a significant difference from placebo in the amount of reduction in QMG scores, while neither of the other two monoclonal antibodies was statistically significant. With regard to the safety of monoclonal antibody therapy, there was no significant difference in the probability of AE in subjects treated with any of the four monoclonal antibodies compared to placebo.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> eculizumab was effective in reducing MG-ADL scores and QMG scores in myasthenia gravis. Meanwhile, eculizumab also caused fewer AE. As an emerging therapy, monoclonal antibodies are prospective in the treatment of MG. However, more researches are required to be invested in the future as the results obtained from small sample sizes are not reliable enough.<\/jats:p>","DOI":"10.3389\/fphar.2021.790834","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:12:12Z","timestamp":1642482732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhaoming","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeya","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal Antibody-Based Therapies for Myasthenia Gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","article-title":"Complement Inhibitor Therapy for Myasthenia Gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nrl.2014.09.007","article-title":"Prevalence of Myasthenia Gravis in the Catalan County of Osona","volume":"32","author":"Aragon\u00e8s","year":"2017","journal-title":"Neurologia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical Predictors of Steroid-Induced Exacerbation in Myasthenia Gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A Review in Systemic Lupus Erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14195","article-title":"Myasthenia Gravis and Specific Immunotherapy: Monoclonal Antibodies","volume":"1452","author":"Cai","year":"2019","journal-title":"Ann. N. Y Acad. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for Lipoprotein Receptor-Related Protein 4-, Agrin-, and Titin-Antibodies and Exploring the Autoimmune Spectrum in Myasthenia Gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J. Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in Myasthenia Gravis in the Era of Biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/ene.13867","article-title":"Sensitivity of MG-ADL for Generalized Weakness in Myasthenia Gravis","volume":"26","author":"de Meel","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1474-4422(18)30037-1","article-title":"Distinct Representation of Muscle Weakness in QMG and MG-ADL","volume":"17","author":"de Meel","year":"2018","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A Review in Generalized Myasthenia Gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11940-014-0283-8","article-title":"Treatment of MuSK-Associated Myasthenia Gravis","volume":"16","author":"El-Salem","year":"2014","journal-title":"Curr. Treat. Options. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","article-title":"Myasthenia Gravis: New Developments in Research and Treatment","volume":"30","author":"Evoli","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of Myasthenia Gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis","volume":"10","author":"Gable","year":"2019","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/nejmra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease Control and Safety of Belimumab Plus Standard Therapy over 7 Years in Patients with Systemic Lupus Erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime Course of Myasthenia Gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized Study of Adjunctive Belimumab in Participants with Generalized Myasthenia Gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(18)30036-X","article-title":"Distinct Representation of Muscle Weakness in QMG and MG-ADL - Authors' Reply","volume":"17","author":"Howard","year":"2018","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0126579","DOI":"10.1371\/journal.pone.0126579","article-title":"Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study","volume":"10","author":"Konno","year":"2015","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","article-title":"Diagnosis and Treatment of Myasthenia Gravis","volume":"31","author":"Mantegazza","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent Improvement with Eculizumab across Muscle Groups in Myasthenia Gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann. Clin. Transl Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Semin. Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/mus.26910","article-title":"Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living Scales in the MGTX Study","volume":"62","author":"McPherson","year":"2020","journal-title":"Muscle Nerve"},{"key":"B35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: Still a Relevant Outcome Measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"B36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does Change in Acetylcholine Receptor Antibody Level Correlate with Clinical Change in Myasthenia Gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"B38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/nyas.13537","article-title":"Developing Treatment Guidelines for Myasthenia Gravis","volume":"1412","author":"Sanders","year":"2018","journal-title":"Ann. N. Y Acad. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e2019013","DOI":"10.4178\/epih.e2019013","article-title":"Network Meta-Analysis: Application and Practice Using R Software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol. Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","article-title":"Generation and Characterization of a High Affinity Anti-human FcRn Antibody, Rozanolixizumab, and the Effects of Different Molecular Formats on the Reduction of Plasma IgG Concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated Generation of Node-Splitting Models for Assessment of Inconsistency in Network Meta-Analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"key":"B43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating Network Meta-Analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and Inconsistency in Network Meta-Analysis: Model Estimation Using Multivariate Meta-Regression","volume":"3","author":"White","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia Gravis Activities of Daily Living Profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.790834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:12:17Z","timestamp":1642482737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.790834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":45,"alternative-id":["10.3389\/fphar.2021.790834"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.790834","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"790834"}}